Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
— First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity — — European Commission grants authorization…
